Novartis set to overcome $14 billion patent cliff say analys...

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said.

AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a

AZ reportedly mulls biggest-ever pharma merger with Gilead

Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <

NodThera raises $55m in Series B round to trial inflammatory...

The Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory diseases drugs for clinical trials. 

Failed trial puts future of UCB’s epilepsy drug padsevonil i...

Novartis says mid-stage pipeline is setting up strong growth...